BIOMAT Database Logo BIOMAT Database Logo

Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. 1994

E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Department of Clinical Pathophysiology, University of Turin, Italy.

Although both spontaneous and stimulated GH secretion undergo an age-related decline, the secretory capacity of somatotrope cells is preserved in human aging. In the present study we compared the GH responses to hexarelin, GHRH, and the combined administration of hexarelin and GHRH or arginine in young and elderly subjects. Thirteen young (24- to 30-yr-old) and 16 elderly (65- to 84-yr-old) normal males were divided into 2 groups. The first group (7 young and 8 elderly subjects) received the following as single iv injections during 3 different treatment sessions: hexarelin (2 micrograms/kg), GHRH (2 micrograms/kg), or hexarelin (2 micrograms/kg) plus GHRH (2 micrograms/kg). The second group (6 young and 8 elderly subjects) was administered single iv injections of hexarelin (2 micrograms/kg) or hexarelin (2 micrograms/kg) plus arginine (0.5 g/kg) during 2 different treatment sessions. In both groups basal IGF-I levels in the elderly were lower than those in young subjects (114.5 +/- 18.7 vs. 211.5 +/- 19.1 micrograms/L; P < 0.001). In the first group the GH response to hexarelin was greater in young compared to elderly subjects (area under the curve from 0-120 = 4849 +/- 601 vs. 2112 +/- 683 micrograms.min/L; P < 0.001). GHRH elicited a lower GH response than that induced by hexarelin in both young (1455 +/- 102 micrograms/h.L; P < 0.02) and elderly subjects (563 +/- 87 micrograms/min.L; P < 0.02). GHRH potentiated the somatotrope response to hexarelin in both young (7725 +/- 503 micrograms/min.L; P < 0.02) and elderly subjects (3895 +/- 612 micrograms/min.L; P < 0.02), but to a lesser extent in the latter (P < 0.001). In the second group, the GH response induced by hexarelin was also higher in young subjects than in elderly subjects (4819 +/- 668 vs. 1649 +/- 459 micrograms/min.L; P < 0.001). The GH response to hexarelin was potentiated by arginine in elderly (4139 +/- 1057 micrograms/min. L; P < 0.001), but not in young subjects (4743 +/- 774 micrograms/min.L). This study shows that the maximal effective dose of hexarelin releases more GH than the maximal effective dose of GHRH in both normal young and elderly subjects. The effect of hexarelin on GH secretion is age dependent, and the GH response to the combined administration of hexarelin and GHRH was significantly higher in young subjects compared to elderly subjects. Arginine does not potentiate the GH response to hexarelin in young subjects, whereas it significantly enhances it in elderly subjects.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate

Related Publications

E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.
May 1992, Metabolism: clinical and experimental,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.
May 1999, Journal of endocrinological investigation,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat.
October 1996, European journal of endocrinology,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Growth hormone-releasing activity of hexarelin in humans. A dose-response study.
January 1994, European journal of clinical pharmacology,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
December 1998, Minerva endocrinologica,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats.
January 1994, Life sciences,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).
October 1994, Clinical endocrinology,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
May 1996, Clinical endocrinology,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
February 1995, The Journal of clinical endocrinology and metabolism,
E Arvat, and L Gianotti, and S Grottoli, and B P Imbimbo, and V Lenaerts, and R Deghenghi, and F Camanni, and E Ghigo
The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects.
November 1998, Clinical endocrinology,
Copied contents to your clipboard!